Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Allogene Therapeutics

General information

Main focus: Allogeneic CAR-T cell therapies

Company stage: Clinical

Diseases: Non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), acute myeloid leukaemia (AML), renal cell carcinoma (RCC), small cell lung cancer (SCLC)

Genome editing tool: TALEN

Funding stage: Public (NASDAQ:ALLO)

Location: San Francisco, CA, USA



Partners: Cellectis, Servier, Notch Therapeutics, SpringWorks Therapeutics, Pfizer

Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Allogene is developing a pipeline ofoff-the-shelf CAR-T cell therapy candidates, with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients.


HashtagAllogene Therapeutics, Inc.

Company: Allogene Therapeutics
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine